Label: TRAZODONE HYDROCHLORIDE Tablet - DailyMed
- Label RSS
View Package Photos
VIEW MORE
Drug Label Info
Safety
- Boxed Warnings
- Report Adverse Events
- FDA Safety Recalls
- Presence in Breast Milk
Related Resources
- Medline Plus
- Clinical Trials
- PubMed
- All Citations
- Adverse Effects
- Therapeutic Use
- Pharmacology
- Clinical Trials
- Biochemical Data Summary
More Info For This Drug
- View Labeling Archives
- RxNorm
- Get Label RSS Feed
- View NDC Code(s)NEW!
- NDC Code(s): 13107-079-01, 13107-079-05, 13107-079-30, 13107-079-99, view more 13107-080-01, 13107-080-05, 13107-080-30, 13107-080-99, 13107-081-01, 13107-081-05, 13107-081-30, 13107-081-99, 13107-082-01, 13107-082-05, 13107-082-30, 13107-082-99
- Packager: Aurolife Pharma LLC
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Drug Label Information
Updated July 5, 2024
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Medication Guide: HTML
- Official Label (Printer Friendly)
- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRAZODONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for TRAZODONE HYDROCHLORIDE TABLETS. TRAZODONE HYDROCHLORIDE tablets, for oral use Initial U.S. Approval: 1981 WARNING: SUICIDAL THOUGHTS and BEHAVIORS See full prescribing information for complete boxed warning.
- Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients (5.1)
- Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors (5.1)
- Trazodone Hydrochloride Tablets are not approved for use in pediatric patients (8.4)
Trazodone Hydrochloride Tablets are a selective serotonin reuptake inhibitor indicated for the treatment of major depressive disorder (MDD) (1).
DOSAGE AND ADMINISTRATION- Starting dose: 150 mg in divided doses daily. May be increased by 50 mg per day every three to four days. Maximum dose: 400 mg per day in divided doses (2).
- Trazodone Hydrochloride Tablets should be taken shortly after a meal or light snack (2).
- Tablets should be swallowed whole or broken in half along the score line, and should not be chewed or crushed (2).
- When discontinued, gradual dose reduction is recommended (2).
- Scored tablets: 50 mg, 100 mg, 150 mg and 300 mg (3).
- Concomitant use of monoamine oxidase inhibitors (MAOIs), or use within 14 days of stopping MAOIs (4).
- Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. If it occurs, discontinue Trazodone Hydrochloride Tablets and initiate supportive treatment (5.2).
- Cardiac Arrhythmias: Increases the QT interval. Avoid use with drugs that also increase the QT interval and in patients with risk factors for prolonged QT interval (5.3)
- Orthostatic Hypotension and Syncope: Warn patients of risk and symptoms of hypotension (5.4).
- Increased Risk of Bleeding: Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), other antiplatelet drugs, warfarin, and other anticoagulants may increase this risk (5.5).
- Priapism: Cases of painful and prolonged penile erections and priapism have been reported. Immediate medical attention should be sought if signs and symptoms of prolonged penile erections or priapism are observed (5.6).
- Activation of Mania or Hypomania: Screen for bipolar disorder and monitor for mania or hypomania (5.7).
- Potential for Cognitive and Motor Impairment: Has potential to impair judgment, thinking, and motor skills. Advise patients to use caution when operating machinery (5.9).
- Angle-Closure Glaucoma: Avoid use of antidepressants, including Trazodone Hydrochloride Tablets, in patients with untreated anatomically narrow angles. (5.10).
Most common adverse reactions (incidence ≥ 5% and twice that of placebo) are: edema, blurred vision, syncope, drowsiness, fatigue, diarrhea, nasal congestion, weight loss (6).
To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
DRUG INTERACTIONS- CNS Depressants: Trazodone Hydrochloride Tablets may enhance effects of alcohol, barbiturates, or other CNS depressants (7).
- CYP3A4 Inhibitors: Consider Trazodone Hydrochloride Tablets dose reduction based on tolerability (2.5, 7).
- CYP3A4 Inducers: Increase in Trazodone Hydrochloride Tablets dosage may be necessary (2.5, 7).
- Digoxin or Phenytoin: Monitor for increased digoxin or phenytoin serum levels (7).
- Warfarin: Monitor for increased or decreased prothrombin time (7).
See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
Revised: 5/2023
- Table of Contents FULL PRESCRIBING INFORMATION: CONTENTS* WARNING: SUICIDAL THOUGHTS AND BEHAVIORS 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION
2.1 Dose Selection
2.2 Important Administration Instructions
2.3 Screen for Bipolar Disorder Prior to Starting Trazodone Hydrochloride Tablets
2.4 Switching to or from Monoamine Oxidase Inhibitor Antidepressant
2.5 Dosage Recommendations for Concomitant Use with Strong CYP3A4 Inhibitors or Inducers
2.6 Discontinuation of Treatment with Trazodone Hydrochloride Tablets
3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS5.1 Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients
5.2 Serotonin Syndrome
5.3 Cardiac Arrhythmias
5.4 Orthostatic Hypotension and Syncope
5.5 Increased Risk of Bleeding
5.6 Priapism
5.7 Activation of Mania or Hypomania
5.8 Discontinuation Syndrome
5.9 Potential for Cognitive and Motor Impairment
5.10 Angle-Closure Glaucoma
5.11 Hyponatremia
6 ADVERSE REACTIONS6.1 Clinical Trials Experience
6.2 Post marketing Experience
7 DRUG INTERACTIONS7.1 Drugs Having Clinically Important Interactions with Trazodone Hydrochloride Tablets
8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy
8.2 Lactation
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment
9 DRUG ABUSE AND DEPENDENCE9.1 Controlled Substance
9.2 Abuse
10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION * Sections or subsections omitted from the full prescribing information are not listed. - BOXED WARNING (What is this?) WARNING: SUICIDAL THOUGHTS AND BEHAVIORS
Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1)]. Trazodone Hydrochloride Tablets are not approved for use in pediatric patients [see Use in Specific Populations (8.4)].
- 1 INDICATIONS AND USAGE
Trazodone Hydrochloride Tablets are indicated for the treatment of major depressive disorder (MDD) in adults.
- 2 DOSAGE AND ADMINISTRATION
2.1 Dose Selection
An initial dose of 150 mg/day in divided doses is suggested. The dosage should be initiated at a low-dose and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage. The dose may be increased by 50 mg/day every 3 to 4 days. The maximum dose for outpatients usually should not exceed 400 mg/day in divided doses. Inpatients (i.e., more severely depressed patients) may be given up to but not in excess of 600 mg/day in divided doses. Once an adequate response has been achieved, dosage may be gradually reduced, with subsequent adjustment depending on therapeutic response.
2.2 Important Administration Instructions
Trazodone Hydrochloride Tablets can be swallowed whole or administered as a half tablet by breaking the tablet along the score line. Trazodone Hydrochloride Tablets should be taken shortly after a meal or light snack.
2.3 Screen for Bipolar Disorder Prior to Starting Trazodone Hydrochloride Tablets
Prior to initiating treatment with Trazodone Hydrochloride Tablets or another antidepressant, screen patients for a personal or family history of bipolar disorder, mania, or hypomania [see Warnings and Precautions (5.7)].
2.4 Switching to or from Monoamine Oxidase Inhibitor Antidepressant
At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOI) antidepressant and initiation of Trazodone Hydrochloride Tablets. In addition, at least 14 days must elapse after stopping Trazodone Hydrochloride Tablets before starting an MAOI antidepressant [see Contraindications (4), Warnings and Precautions (5.2)].
2.5 Dosage Recommendations for Concomitant Use with Strong CYP3A4 Inhibitors or Inducers
Coadministration with Strong CYP3A4 Inhibitors Consider reducing Trazodone Hydrochloride Tablets dose based on tolerability when Trazodone Hydrochloride Tablets are coadministered with a strong CYP3A4 inhibitor [see Drug Interactions (7.1)].
Coadministration with Strong CYP3A4 Inducers Consider increasing Trazodone Hydrochloride Tablets dose based on therapeutic response when Trazodone Hydrochloride Tablets are coadministered with a strong CYP3A4 inducer [see Drug Interactions (7.1)].
2.6 Discontinuation of Treatment with Trazodone Hydrochloride Tablets
Adverse reactions may occur upon discontinuation of Trazodone Hydrochloride Tablets [See Warnings and Precautions (5.8)]. Gradually reduce the dosage rather than stopping Trazodone Hydrochloride Tablets abruptly whenever possible.
- 3 DOSAGE FORMS AND STRENGTHS
Trazodone hydrochloride tablets USP are available in the following strengths:
- 50 mg: White to off-white, round, biconvex, uncoated tablets, debossed with ‘J’ and ‘43’ on either side of scoreline (functional) on one side and plain on the other side.
- 100 mg: White to off-white, round, biconvex, uncoated tablets, debossed with ‘J’ and ‘44’ on either side of scoreline (functional) on one side and plain on the other side.
- 150 mg: White to off-white, oval, flat faced, beveled-edge, uncoated tablets with one side scored (functional) with full bisect debossed with ‘J’ and ‘45’ on either side and having two partial trisect on one side and plain on the other side.
- 300 mg: White to off-white, oval, flat faced, beveled-edge, uncoated tablets with one side scored (functional) with full bisect debossed with ‘J’ and ‘46’ on either side and having two partial trisect on one side and plain on the other side.
- 4 CONTRAINDICATIONS
Trazodone Hydrochloride Tablets are contraindicated in:
- Patients taking, or within 14 days of stopping, monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue, because of an increased risk of serotonin syndrome [see Warnings and Precautions (5.2), Drug Interactions (7.1)].
- 5 WARNINGS AND PRECAUTIONS
5.1 Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients
In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and over 4,400 pediatric patients, the incidence of suicidal thoughts and behaviors in pediatric and young adult patients was greater in antidepressant-treated patients than in placebo-treated patients. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1000 patients treated are provided in Table 1.
No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about antidepressant drug effect on suicide.
Table 1: Risk Differences of the Number of Cases of Suicidal Thoughts or Behaviors in the Pooled Placebo-Controlled
Age Range (years) Drug-Placebo Differencein Number of Patients of Suicidal Thoughts or Behaviors per 1000 Patients Treated Increases Compared to Placebo <18 14 additional patients 18-24 5 additional patients Decreases Compared to Placebo 25-64 1 fewer patient ≥65 6 fewer patients It is unknown whether the risk of suicidal thoughts and behaviors in pediatric and young adult patients extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression.
Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing Trazodone Hydrochloride Tablets, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.
5.2 Serotonin Syndrome
Serotonin-norepinephrine reuptake inhibitors (SNRIs) and SSRIs, including Trazodone Hydrochloride Tablets, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see Contraindications (4), Drug Interactions (7.1)]. Serotonin syndrome can also occur when these drugs are used alone.
Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).
The concomitant use of Trazodone Hydrochloride Tablets with MAOIs is contraindicated. In addition, do not initiate Trazodone Hydrochloride Tablets in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking Trazodone Hydrochloride Tablets, discontinue Trazodone Hydrochloride Tablets before initiating treatment with the MAOI [see Contraindications (4), Drug Interactions (7.1)].
Monitor all patients taking Trazodone Hydrochloride Tablets for the emergence of serotonin syndrome. Discontinue treatment with Trazodone Hydrochloride Tablets and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of Trazodone Hydrochloride Tablets with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.
5.3 Cardiac Arrhythmias
Clinical studies indicate that trazodone hydrochloride may be arrhythmogenic in patients with preexisting cardiac disease. Arrhythmias identified include isolated PVCs, ventricular couplets, tachycardia with syncope, and torsade de pointes. Post marketing events, including torsade de pointes have been reported at doses of 100 mg or less with the immediate-release form of Trazodone Hydrochloride Tablets. Trazodone Hydrochloride Tablets should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and the presence of congenital prolongation of the QT interval. Trazodone Hydrochloride Tablets are not recommended for use during the initial recovery phase of myocardial infarction. Caution should be used when administering Trazodone Hydrochloride Tablets to patients with cardiac disease and such patients should be closely monitored, since antidepressant drugs (including Trazodone Hydrochloride Tablets) may cause cardiac arrhythmias [see Adverse Reactions (6.2)].
Trazodone Hydrochloride Tablets prolongs the QT/QTc interval. The use of Trazodone Hydrochloride Tablets should be avoided in patients with known QT prolongation or in combination with other drugs that are inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, voriconazole), or known to prolong QT interval including Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class 3 antiarrhythmics (e.g., amiodarone, sotalol), certain antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), and certain antibiotics (e.g., gatifloxacin). Concomitant administration of drugs may increase the risk of cardiac arrhythmia [see Drug Interactions (7.1)].
5.4 Orthostatic Hypotension and Syncope
Hypotension, including orthostatic hypotension and syncope has been reported in patients receiving trazodone hydrochloride. Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug.
5.5 Increased Risk of Bleeding
Drugs that interfere with serotonin reuptake inhibition, including Trazodone Hydrochloride Tablets, increase the risk of bleeding events. Concomitant use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDS), other antiplatelet drugs, warfarin, and other anticoagulants may add to this risk.
Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Bleeding events related to drugs that interfere with serotonin reuptake have ranged from ecchymosis, hematoma, epistaxis, and petechiae to life-threatening hemorrhages. Inform patients about the risk of bleeding associated with the concomitant use of Trazodone Hydrochloride Tablets and antiplatelet agents or anticoagulants. For patients taking warfarin, carefully monitor coagulation indices when initiating, titrating, or discontinuing Trazodone Hydrochloride Tablets.
5.6 Priapism
Cases of priapism (painful erections greater than 6 hours in duration) have been reported in men receiving Trazodone Hydrochloride Tablets. Priapism, if not treated promptly, can result in irreversible damage to the erectile tissue. Men who have an erection lasting greater than 4 hours, whether painful or not, should immediately discontinue the drug and seek emergency medical attention [see Adverse Reactions (6.2), Overdosage (10)].
Trazodone Hydrochloride Tablets should be used with caution in men who have conditions that might predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia), or in men with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie’s disease).
5.7 Activation of Mania or Hypomania
In patients with bipolar disorder, treating a depressive episode with Trazodone Hydrochloride Tablets or another antidepressant may precipitate a mixed/manic episode. Activation of mania/hypomania has been reported in a small proportion of patients with major affective disorder who were treated with antidepressants. Prior to initiating treatment with Trazodone Hydrochloride Tablets, screen patients for any personal or family history of bipolar disorder, mania, or hypomania [see Dosage and Administration (2.3)].
5.8 Discontinuation Syndrome
Adverse reactions after discontinuation of serotonergic antidepressants, particularly after abrupt discontinuation, include: nausea, sweating, dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesia, such as electric shock sensations), tremor, anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. A gradual reduction in dosage rather than abrupt cessation is recommended whenever possible [See Dosage and Administration (2.6)].
5.9 Potential for Cognitive and Motor Impairment
Trazodone Hydrochloride Tablets may cause somnolence or sedation and may impair the mental and/or physical ability required for the performance of potentially hazardous tasks. Patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that the drug treatment does not affect them adversely.
5.10 Angle-Closure Glaucoma
The pupillary dilation that occurs following use of many antidepressant drugs including Trazodone Hydrochloride Tablets may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Avoid use of antidepressants, including Trazodone Hydrochloride Tablets, in patients with untreated anatomically narrow angles.
5.11 Hyponatremia
Hyponatremia may occur as a result of treatment with SNRIs and SSRIs, including Trazodone Hydrochloride Tablets. Cases with serum sodium lower than 110 mmol/L have been reported. Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which can lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death. In many cases, this hyponatremia appears to be the result of the syndrome of inappropriate antidiuretic hormone secretion (SIADH).
In patients with symptomatic hyponatremia, discontinue Trazodone Hydrochloride Tablets and institute appropriate medical intervention. Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations (8.5)].
- 6 ADVERSE REACTIONS
The following serious adverse reactions are described elsewhere in the labeling:
- Suicidal Thoughts and Behavior in Children, Adolescents and Young Adults [see Boxed Warning and Warnings and Precautions (5.1)]
- Serotonin Syndrome [see Warnings and Precautions (5.2)]
- Cardiac Arrythmias [see Warnings and Precautions (5.3)]
- Orthostatic Hypotension and Syncope [see Warnings and Precautions (5.4)]
- Increased Risk of Bleeding [see Warnings and Precautions (5.5)]
- Priapism [see Warnings and Precautions (5.6)]
- Activation of Mania or Hypomania [see Warnings and Precautions (5.7)]
- Discontinuation Syndrome [see Warnings and Precautions (5.8)]
- Potential for Cognitive and Motor Impairment [see Warnings and Precautions (5.9)]
- Angle-Closure Glaucoma [see Warnings and Precautions (5.10)]
- Hyponatremia [see Warnings and Precautions (5.11)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Table 2: Common Adverse Reactions Occurring in ≥ 2% of Trazodone Hydrochloride Tablets-treated Patients and Greater than the Rate of Placebo-Treated Patients as Observed in Controlled Clinical Studies
Inpatients Outpatients Trazodone Hydrochloride TabletsN=142 Placebo N=95 Trazodone Hydrochloride TabletsN=157 PlaceboN=158 Allergic Skin Condition/Edema 3% 1% 7% 1% Autonomic Blurred Vision 6% 4% 15% 4% Constipation 7% 4% 8% 6% Dry Mouth 15% 8% 34% 20% Cardiovascular Hypertension 20% 1% 1% * Hypotension 7% 1% 4% 0 Syncope 3% 2% 5% 1% CNS Confusion 5% 0 6% 8% Decreased Concentration 3% 2% 1% 0 Disorientation 2% 0 * 0 Fatigue 11% 4% 6% 3% Headache 10% 5% 20% 16% Nervousness 15% 11% 6% 8% Gastrointestinal Abdominal/Gastric Disorder 4% 4% 6% 4% Diarrhea 0 1% 5% 1% Nausea/Vomiting 10% 1% 13% 10% Musculoskeletal Aches/Pains 6% 3% 5% 3% Neurological Incoordination 5% 0 2% * Tremors 3% 1% 5% 4% Other Eyes Red/Tired/Itching 3% 0 0 0 Head Full-Heavy 3% 0 0 0 Malaise 3% 0 0 0 Nasal/Sinus Congestion 3% 0 6% 3% Weight Gain 1% 0 5% 2% Weight Loss * 3% 6% 3% Other adverse reactions occurring at an incidence of <2% with the use of trazodone hydrochloride in the controlled clinical studies: akathisia, allergic reaction, anemia, chest pain, delayed urine flow, early menses, flatulence, hallucinations/delusions, hematuria, hypersalivation, hypomania, impaired memory, impaired speech, impotence, increased appetite, increased libido, increased urinary frequency, missed periods, muscle twitches, numbness, paresthesia, retrograde ejaculation, shortness of breath, and tachycardia/palpitations. Occasional sinus bradycardia has occurred in long-term studies.
6.2 Post marketing Experience
The following adverse reactions have been identified during post-approval use of Trazodone Hydrochloride Tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency or establish a causal relationship to drug exposure:
Blood and lymphatic system disorders: hemolytic anemia, leukocytosis
Cardiac disorders: cardio spasm, congestive heart failure, conduction block, orthostatic hypotension and syncope, palpitations, bradycardia, atrial fibrillation, myocardial infarction, cardiac arrest, arrhythmia, ventricular ectopic activity, including ventricular tachycardia and QT prolongation. Prolonged QT interval, torsade de pointes, and ventricular tachycardia have been reported at doses of 100 mg per day or less [see Warnings and Precautions (5.3)]. Endocrine disorders: inappropriate ADH syndrome Eye disorders: diplopia Gastrointestinal disorders: increased salivation, nausea/vomiting General disorders and administration site conditions: chills, edema, unexplained death, weakness Hepatobiliary disorders: cholestasis, jaundice, hyperbilirubinemia, liver enzyme alterations Investigations: increased amylase Metabolism and nutrition disorders: methemoglobinemia Nervous system disorders: aphasia, ataxia, cerebrovascular accident, extrapyramidal symptoms, grand mal seizures, paresthesia, tardive dyskinesia, vertigo Psychiatric disorders: abnormal dreams, agitation, anxiety, hallucinations, insomnia, paranoid reaction, psychosis, stupor Renal and urinary disorders: urinary incontinence, urinary retention Reproductive system and breast disorders: breast enlargement or engorgement, clitorism, lactation, priapism [see Warnings and Precautions (5.6)] Respiratory, thoracic and mediastinal disorders: apnea Skin and subcutaneous tissue disorders: alopecia, hirsutism, leukonychia, pruritus, psoriasis, rash, urticaria Vascular disorders: vasodilation
- 7 DRUG INTERACTIONS
7.1 Drugs Having Clinically Important Interactions with Trazodone Hydrochloride Tablets
Table 3: Clinically Important Drug Interactions with Trazodone Hydrochloride Tablets
Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: The concomitant use of MAOIs and serotonergic drugs including Trazodone hydrochloride tablets increases the risk of serotonin syndrome. Intervention: Trazodone hydrochloride tablets are contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Contraindications (4), Dosage and Administration (2.3, 2.4), and Warnings and Precautions (5.2)]. Examples: isocarboxazid, moclobemide, phenelzine, selegiline, tranylcypromine Other Serotonergic Drugs Clinical Impact: The concomitant use of serotonergic drugs including Trazodone hydrochloride tablets and other serotonergic drugs increases the risk of serotonin syndrome. Intervention: Monitor patients for signs and symptoms of serotonin syndrome, particularly during Trazodone hydrochloride tablets initiation. If serotonin syndrome occurs, consider discontinuation of Trazodone hydrochloride tablets and/or concomitant serotonergic drugs [see Warnings and Precautions (5.2)]. Examples: triptans, antidepressants (tricyclic and serotonin uptake inhibitors), fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John's Wort Antiplatelet Agents and Anticoagulants Clinical Impact: Serotonin release by platelets plays an important role in hemostasis. The concurrent use of an antiplatelet agent or anticoagulant with Trazodone hydrochloride tablets may potentiate the risk of bleeding. Intervention: Inform patients of the increased risk of bleeding with the concomitant use of Trazodone hydrochloride tablets and antiplatelet agents and anticoagulants. For patients taking warfarin, carefully monitor the international normalized ratio (INR) when initiating or discontinuing Trazodone hydrochloride tablets [see Warnings and Precautions (5.5)]. Examples: warfarin, rivaroxaban, dabigatran, clopidogrel Strong CYP3A4 Inhibitors Clinical Impact: The concomitant use of Trazodone hydrochloride tablets and strong CYP3A4 inhibitors increased the exposure of trazodone compared to the use of Trazodone hydrochloride tablets alone. Intervention: If Trazodone hydrochloride tablets are used with a potent CYP3A4 inhibitor, the risk of adverse reactions, including cardiac arrhythmias, may be increased and a lower dose of Trazodone hydrochloride tablets should be considered [see Dosage and Administration (2.5), Warnings and Precautions (5.3)]. Examples: itraconazole, ketoconazole, clarithromycin, indinavir Strong CYP3A4 Inducers Clinical Impact: The concomitant use of Trazodone hydrochloride tablets and strong CYP3A4 inducers decreased the exposure of trazodone compared to the use of Trazodone hydrochloride tablets alone. Intervention: Patients should be closely monitored to see if there is a need for an increased dose of Trazodone hydrochloride tablets when taking CYP3A4 inducers [see Dosage and Administration (2.5)]. Examples: rifampin, carbamazepine, phenytoin, St. John’s wort Digoxin and Phenytoin Clinical Impact: Digoxin and phenytoin are narrow therapeutic index drugs. Concomitant use of Trazodone hydrochloride tablets can increase digoxin or phenytoin concentrations. Intervention: Measure serum digoxin or phenytoin concentrations before initiating concomitant use of Trazodone hydrochloride tablets. Continue monitoring and reduce digoxin or phenytoin dose as necessary. Examples: digoxin, phenytoin Central Nervous System (CNS) Depressants Clinical Impact: Trazodone hydrochloride tablets may enhance the response CNS depressants. Intervention: Patients should be counseled that Trazodone hydrochloride tablets may enhance the response to alcohol, barbiturates, and other CNS depressants. Examples: alcohol, barbiturates QT Interval Prolongation Clinical Impact: Concomitant use of drugs that prolong the QT interval may add to the QT effects of Trazodone hydrochloride tablets and increase the risk of cardiac arrhythmia. Intervention Avoid the use of Trazodone hydrochloride tablets in combination with other drugs known to prolong QTc [see Warnings and Precautions (5.3)]. Examples: Class 1A antiarrhythmics: quinidine, procainamide, disopyramide; Class 3 antiarrhythmics: amiodarone, sotalol; Antipsychotics: ziprasidone, chlorpromazine, thioridazine; Antibiotics: gatifloxacin - 8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405- 6185 or visiting online at https://womensmentalhealth.org/clinical-and-research programs/pregnancy registry/antidepressants/
Risk Summary
Published prospective cohort studies, case series, and case reports over several decades with Trazodone Hydrochloride Tablets use in pregnant women have not identified any drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see Data). Trazodone hydrochloride has been shown to cause increased fetal resorption and other adverse effects on the fetus in the rat when given at dose levels approximately 7.3 to 11 times the maximum recommended human dose (MRHD) of 400 mg/day in adults on a mg/m2 basis. There was also an increase in congenital anomalies in the rabbit at approximately 7.3 to 22 times the MRHD on a mg/m2 basis (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations
Disease-associated maternal and/or embryo fetal risk
A prospective, longitudinal study followed 201 pregnant women with a history of major depressive disorder who were euthymic and taking antidepressants at the beginning of pregnancy. The women who discontinued antidepressants during pregnancy were more likely to experience a relapse of major depression that women who continued antidepressants. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.
Data
Human Data
While available studies cannot definitively establish the absence of risk, published data from prospective cohort studies, case series, and case reports over several decades have not identified an association with trazodone use during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. All available studies have methodological limitations, including small sample size and inconsistent comparator groups.
Animal Data
No teratogenic effects were observed when trazodone was given to pregnant rats and rabbits during the period of organogenesis at oral doses up to 450 mg/kg/day. This dose is 11 and 22 times, in rats and rabbits, respectively, the maximum recommended human dose (MRHD) of 400 mg/day in adults on a mg/m2 basis. Increased fetal resorption and other adverse effects on the fetus in rats at 7.3 to 11 times the MRHD and increase in congenital anomalies in rabbits at 7.3 to 22 times the MRHD on a mg/m2 basis were observed. No further details on these studies are available.
8.2 Lactation
Risk Summary
Data from published literature report the transfer of trazodone into human milk. There are no data on the effect of trazodone on milk production. Limited data from post marketing reports have not identified and association of adverse effects on the breastfed child. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Trazodone Hydrochloride Tablets and any potential adverse effects on the breastfed child from Trazodone Hydrochloride Tablets or from the underlying maternal condition.
8.4 Pediatric Use
Safety and effectiveness in the pediatric population have not been established. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients [see Boxed Warning, Warnings and Precautions (5.1)].
8.5 Geriatric Use
Reported clinical literature and experience with trazodone has not identified differences in responses between elderly and younger patients. However, as experience in the elderly with trazodone hydrochloride is limited, it should be used with caution in geriatric patients. Serotonergic antidepressants have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse reaction [see Warnings and Precautions (5.11)].
8.6 Renal Impairment
Trazodone has not been studied in patients with renal impairment. Trazodone should be used with caution in this population.
8.7 Hepatic Impairment
Trazodone has not been studied in patients with hepatic impairment. Trazodone should be used with caution in this population.
- 9 DRUG ABUSE AND DEPENDENCE
9.1 Controlled Substance
Trazodone Hydrochloride Tablets are not a controlled substance.
9.2 Abuse
Although trazodone hydrochloride has not been systematically studied in preclinical or clinical studies for its potential for abuse, no indication of drug-seeking behavior was seen in the clinical studies with trazodone hydrochloride.
- 10 OVERDOSAGE
Death from overdose has occurred in patients ingesting Trazodone Hydrochloride Tablets and other CNS depressant drugs concurrently (alcohol; alcohol and chloral hydrate and diazepam; amobarbital; chlordiazepoxide; or meprobamate).
The most severe reactions reported to have occurred with overdose of Trazodone Hydrochloride Tablets alone have been priapism, respiratory arrest, seizures, and ECG changes, including QT prolongation. The reactions reported most frequently have been drowsiness and vomiting. Overdosage may cause an increase in incidence or severity of any of the reported adverse reactions.
There is no specific antidote for trazodone hydrochloride overdose. In managing overdosage, consider the possibility of multiple drug involvement. For current information on the management of poisoning or overdose, contact a poison control center (1-800-222-1222 or www.poison.org).
- 11 DESCRIPTION
Trazodone hydrochloride tablets for oral administration contain trazodone hydrochloride, a selective serotonin reuptake inhibitor and 5HT2 receptor antagonist. Trazodone hydrochloride is a triazolopyridine derivative designated as 2-[3-[4-(3-chlorophenyl)-1piperazinyl]propyl]-1,2,4-triazolo [4,3-a]pyridin-3(2H)-one hydrochloride. It is a white odorless crystalline powder which is freely soluble in water. The structural formula is represented as follows:
Molecular Formula: C19H22CIN5O • HCl
Molecular Weight: 408.33
Each tablet, for oral administration, contains 50 mg, 100 mg, 150 mg or 300 mg of trazodone hydrochloride, USP. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, pregelatinized starch (physically modified corn (maize) starch), sodium lauryl sulfate, and sodium starch glycolate.
- 12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
The mechanism of trazodone’s antidepressant action is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS. Trazodone is both a selective serotonin reuptake inhibitor (SSRI) and a 5HT2 receptor antagonist and the net result of this action on serotonergic transmission and its role in trazodone’s antidepressant effect is unknown.
12.2 Pharmacodynamics
Preclinical studies have shown that trazodone selectively inhibits neuronal reuptake of serotonin (Ki = 367 nM) and acts as an antagonist at 5-HT-2A (Ki = 35.6 nM) serotonin receptors. Trazodone is also an antagonist at several other monoaminergic receptors including 5-HT2B (Ki = 78.4 nM), 5-HT2C (Ki = 224 nM), α1A (Ki = 153 nM), α2C (Ki = 155 nM) receptors and it is a partial agonist at 5- HT1A (Ki = 118 nM) receptor.
Trazodone antagonizes alpha 1-adrenergic receptors, a property which may be associated with postural hypotension.
12.3 Pharmacokinetics
Absorption
In humans, trazodone hydrochloride is absorbed after oral administration without selective localization in any tissue. When trazodone hydrochloride is taken shortly after ingestion of food, there may be an increase in the amount of drug absorbed, a decrease in maximum concentration and a lengthening in the time to maximum concentration. Peak plasma levels occur approximately one hour after dosing when trazodone hydrochloride is taken on an empty stomach or 2 hours after dosing when taken with food.
Metabolism
In vitro studies in human liver microsomes show that trazodone is metabolized, via oxidative cleavage, to an active metabolite, m- chlorophenylpiperazine (mCPP) by CYP3A4. Other metabolic pathways that may be involved in the metabolism of trazodone have not been well characterized. Trazodone is extensively metabolized; less than 1% of an oral dose is excreted unchanged in the urine.
Elimination
In some patients trazodone may accumulate in the plasma.
Protein Binding
Trazodone is 89 to 95% protein bound in vitro at concentrations attained with therapeutic doses in humans.
- 13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis
No drug- or dose-related occurrence of carcinogenesis was evident in rats receiving trazodone in daily oral doses up to 7.3 times the maximum recommended human dose (MRHD) of 400 mg/day in adults on a mg/m2 basis.
Mutagenesis
No genotoxicity studies were conducted with trazodone.
Impairment of Fertility
Trazodone has no effect on fertility in rats at doses up to 7.3 times the MRHD in adults on a mg/m2 basis.
- 14 CLINICAL STUDIES
The efficacy and safety of trazodone hydrochloride were established from inpatient and outpatient trials of the trazodone immediate release formulation in the treatment of major depressive disorder.
- 16 HOW SUPPLIED/STORAGE AND HANDLING
Trazodone Hydrochloride Tablets, USP 50 mg are white to off-white, round, biconvex, uncoated tablets, debossed with ‘J’ and ‘43’ on either side of scoreline (functional) on one side and plain on the other side.
Bottles of 30 NDC 13107-079-30
Bottles of 100 NDC 13107-079-01
Bottles of 500 NDC 13107-079-05
Bottles of 1,000 NDC 13107-079-99
Trazodone Hydrochloride Tablets, USP 100 mg are white to off-white, round, biconvex, uncoated tablets, debossed with ‘J’ and ‘44’ on either side of scoreline (functional) on one side and plain on the other side.
Bottles of 30 NDC 13107-080-30
Bottles of 100 NDC 13107-080-01
Bottles of 500 NDC 13107-080-05
Bottles of 1,000 NDC 13107-080-99
Trazodone Hydrochloride Tablets, USP 150 mg are white to off-white, oval, flat faced, beveled-edge, uncoated tablets with one side scored (functional) with full bisect debossed with ‘J’ and ‘45’ on either side and having two partial trisect on one side and plain on the other side.
Bottles of 20 NDC 13107-081-20
Bottles of 100 NDC 13107-081-01
Bottles of 500 NDC 13107-081-05
Bottles of 1,000 NDC 13107-081-99
Directions for using the correct score when breaking the tablet, please refer to the following:
-For 50 mg, break the score on either the left or right side of the tablet (one-third of a tablet).
-For 75 mg, break the score down the middle of the tablet (one-half of a tablet).
-For 100 mg, break the score on either the left or right side of the tablet (two-thirds of a tablet).
-For 150 mg, use the entire tablet.
Trazodone Hydrochloride Tablets, USP 300 mg are white to off-white, oval, flat faced, beveled-edge, uncoated tablets with one side scored (functional) with full bisect debossed with ‘J’ and ‘46’ on either side and having two partial trisect on one side and plain on the other side.
Bottles of 100 NDC 13107-082-01
Bottles of 500 NDC 13107-082-05
Directions for using the correct score when breaking the tablet, please refer to the following:
-For 100 mg, break the score on either the left or right side of the tablet (one-third of a tablet)
-For 150 mg, break the score down the middle of the tablet (one-half of a tablet).
-For 200 mg, break the score on either the left or right side of the tablet (two-thirds of a tablet).
-For 300 mg, use the entire tablet.
Store at 20°C to 25°C (68°F to 77°F). Excursions permitted between 15ºC and 30ºC (59°F to 86ºF) [see USP Controlled Room Temperature]. Dispense with a child-resistant closure in a tight, light-resistant container.
- 17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Suicidal Thoughts and Behaviors
Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down and instruct them to report such symptoms to the healthcare provider [see Box Warning and Warnings and Precautions (5.1)].
Dosage and Administration
Advise patients that Trazodone Hydrochloride Tablets should be taken shortly after a meal or light snack. Advise patients regarding the importance of following dosage titration instructions [see Dosage and Administration (2)].
Serotonin Syndrome
Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of Trazodone Hydrochloride Tablets with other serotonergic drugs including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid). Patients should contact their health care provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome [see Warnings and Precautions (5.2) and Drug Interactions (7)].
Activation of Mania/Hypomania
Advise patients and their caregivers to observe for signs of activation of mania/hypomania and instruct them to report such symptoms to the healthcare provider [seeWarnings and Precautions (5.7)].
Increased Risk of Bleeding
Inform patients about the concomitant use of Trazodone Hydrochloride Tablets with aspirin, NSAIDs, other antiplatelet drugs, warfarin, or other anticoagulants because the combined use of drugs that interfere with serotonin reuptake and these medications has been associated with an increased risk of bleeding. Advise them to inform their health care providers if they are taking or planning to take any prescription or over-the-counter medications that increase the risk of bleeding [see Warnings and Precautions (5.5)].
Discontinuation Syndrome
Advise patients not to abruptly discontinue Trazodone Hydrochloride Tablets and to discuss any tapering regimen with their healthcare provider. Adverse reactions can occur when Trazodone Hydrochloride Tablets are discontinued [see Warnings and Precautions (5.8)].
Concomitant Medications
Advise patients to inform their health care providers if they are taking, or plan to take any prescription or over-the-counter medications since there is a potential for interactions [see Drug Interactions (7.1)].
Pregnancy
Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during therapy with Trazodone Hydrochloride Tablets. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Trazodone Hydrochloride Tablets during pregnancy [see Use in Special Populations (8.1)].
Dispense with Medication Guide available at www.aurobindousa.com/medication-guides
Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown RoadEast Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India Revised: 05/2023 Dispense with Medication Guide available at www.aurobindousa.com/medication-guides
- MEDICATION GUIDE
MEDICATION GUIDE Trazodone Hydrochloride Tablets, USP (traz’ oh done hye’’ droeklor’ ide) What is the most important information I should know about Trazodone Hydrochloride Tablets? Antidepressant medicines, depression or other serious mental illnesses, and suicidal thoughts or actions: Talk to your healthcare provider about: - All risks and benefits of treatment with antidepressant medicines
- All treatment choices for depression or other serious mental illnesses
- Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.
- Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts or feelings.
- Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms.
- Thoughts about suicide or dying
- Attempts to commit suicide
- New or worse depression
- New or worse anxiety
- Feeling very agitated or restless
- Panic attacks
- Trouble sleeping (insomnia)
- New or worse irritability
- Acting aggressive, being angry or violent
- Acting on dangerous impulses
- An extreme increase in activity and talking (mania)
- Other unusual changes in behavior or mood
- Never stop an antidepressant medicine without first talking to a healthcare provider. Stopping an antidepressant medicine suddenly can cause other symptoms.
- Antidepressants are medicines used to treat depression and other illnesses. It is important to discuss all the risks of treating depression and also the risks of not treating it. You should discuss all treatment choices with your healthcare provider, not just the use of antidepressants.
- Antidepressant medicines have other side effects. Talk to your healthcare provider about the side effects of your medicines.
- Antidepressant medicines can interact with other medicines. Know all of the medicines that you take. Keep a list of all medicines to show your healthcare provider. Do not start new medicines without first checking with your healthcare provider.
What is Trazodone Hydrochloride Tablets? Trazodone Hydrochloride Tablets are a prescription medicine used in adults to treat major depressive disorder (MDD). Trazodone Hydrochloride Tablets belongs to a class of medicines known as SSRIs (or selective serotonin reuptake inhibitors). Do not take Trazodone Hydrochloride Tablets: - If you take a monoamine oxidase inhibitor (MAOI). Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid, and intravenous methylene blue.
- Do not take an MAOI within 2 weeks of stopping Trazodone Hydrochloride Tablets unless directed to do so by your healthcare provider.
- Do not start Trazodone Hydrochloride Tablets if you stopped taking an MAOI in the last 2 weeks unless directed to do so by your healthcare provider.
Before you take Trazodone Hydrochloride Tablets tell your healthcare provider about all of your medical conditions, including if you: - have heart problems, including QT prolongation or a family history of it
- have ever had a heart attack
- have bipolar disorder
- have liver or kidney problems
- have other serious medical conditions
- are pregnant or plan to become pregnant. It is not known if Trazodone Hydrochloride Tablets will harm your unborn baby. Talk to your healthcare provider about the risk to your unborn baby if you take Trazodone Hydrochloride Tablets.
- If you become pregnant during treatment with Trazodone Hydrochloride Tablets, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants. You can register by calling 1-844-405-6185.
- are breastfeeding or plan to breastfeed. Trazodone Hydrochloride Tablets passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Trazodone Hydrochloride Tablets.
- have taken a Monoamine Oxidase Inhibitor (MAOI) or if you have stopped taking an MAOI in the last 2 weeks.
- triptans used to treat migraine headache
- medicines used to treat mood, anxiety, psychotic or thought disorders, including tricyclics, lithium, SSRIs, SNRIs, buspirone, or antipsychotics
- tramadol
- over-the-counter supplements such as tryptophan or St. John’s Wort
- nonsteroidal anti-inflammatory drugs (NSAIDS)
- aspirin
- warfarin (Coumadin, Jantoven)
- phenytoin (Mesantoin)
- diuretics
How should I take Trazodone Hydrochloride Tablets? - Take Trazodone Hydrochloride Tablets exactly as your healthcare provider tells you.
- Trazodone Hydrochloride Tablets should be taken shortly after a meal or light snack.
- If you feel drowsy after taking Trazodone Hydrochloride Tablets, talk to your healthcare provider. Your healthcare provider may change your dose or the time of day you take your Trazodone Hydrochloride Tablets.
- Do not stop taking Trazodone Hydrochloride Tablets without talking to your healthcare provider.
- Trazodone Hydrochloride Tablets should be swallowed whole or broken in half along the score line. Do not chew or crush Trazodone Hydrochloride Tablets. Tell your healthcare provider if you cannot swallow trazodone either whole or as a half tablet.
- If you take too much Trazodone Hydrochloride Tablets, call your healthcare provider, your Poison Control Center at 1-800-222-1222, or go to the nearest emergency room right away.
What should I avoid while taking Trazodone Hydrochloride Tablets? - Do not drive, operate heavy machinery, or do other dangerous activities until you know how Trazodone Hydrochloride Tablets affects you. Trazodone Hydrochloride Tablets can slow your thinking and motor skills.
- Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking Trazodone Hydrochloride Tablets until you talk with your healthcare provider. Trazodone Hydrochloride Tablets may make your sleepiness or dizziness worse if you take it with alcohol or other medicines that cause sleepiness or dizziness.
What are the possible side effects of Trazodone Hydrochloride Tablets? Trazodone Hydrochloride Tablets can cause serious side effects or death, including: - See “What is the most important information I should know about Trazodone Hydrochloride Tablets?”
- Serotonin syndrome. Symptoms of serotonin syndrome include: agitation, hallucinations, and problems with coordination, fast heartbeat, tight muscles, trouble walking, sweating, fever, nausea, vomiting, and diarrhea.
- Irregular or fast heartbeat or faint (QT prolongation)
- Low blood pressure. You feel dizzy or faint when you change positions (go from sitting to standing)
- Unusual bruising or bleeding
- Erection lasting for more than 6 hours (priapism)
- Feeling high or in a very good mood, then becoming irritable, or having too much energy, feeling like you have to keep talking or do not sleep (mania).
- Withdrawal symptoms. Symptoms of withdrawal can include anxiety, agitation, and sleep problems. Do not stop taking Trazodone Hydrochloride Tablets without talking to your healthcare provider.
- eye pain
- changes in vision
- swelling or redness in or around the eye
- Low sodium in your blood (hyponatremia). Symptoms of hyponatremia include: headache, feeling weak, feeling confused, trouble concentrating, memory problems and feeling unsteady when you walk.
- swelling
- blurred vision
- dizziness
- sleepiness
- tiredness
- diarrhea
- stuffy nose
- weight loss
How should I store Trazodone Hydrochloride Tablets? - Store Trazodone Hydrochloride Tablets at room temperature between 68°F to 77°F (20°C to 25°C).
- Keep in tight container
- Keep out of the light
- Safely throw away medicine that is out of date or no longer needed.
General information about the safe and effective use of Trazodone Hydrochloride Tablets. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Trazodone Hydrochloride Tablets for a condition for which it was not prescribed. Do not give Trazodone Hydrochloride Tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Trazodone Hydrochloride Tablets that is written for health professionals. What are the ingredients in Trazodone Hydrochloride Tablets? Active ingredient: Trazodone Hydrochloride, USP Inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, pregelatinized starch (physically modified corn (maize) starch), sodium lauryl sulfate, and sodium starch glycolate. Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown RoadEast Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad-500 032, India Revised: 05/2023 - PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-50 mg (100 Tablet Bottle)
NDC 13107-079-01
traZODONE Hydrochloride Tablets, USP 50 mg Pharmacist: Please dispense with medication guide provided separately Rx only 100 Tablets AUROBINDO
- PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-100 mg (100 Tablet Bottle)
NDC 13107-080-01
traZODONE Hydrochloride Tablets, USP 100 mg Pharmacist: Please dispense with medication guide provided separately Rx only 100 Tablets AUROBINDO
- PACKAGE LABEL-PRINCIPAL DISPALY PANEL- 150 mg (100 Tablet Bottle)
NDC 13107-081-01
traZODONE Hydrochloride Tablets, USP 150 mg Pharmacist: Please dispense with medication guide provided separately Rx only 100 Tablets AUROBINDO
- PACKAGE LABEL-PRINCIPAL DISPALY PANEL- 300 mg (100 Tablet Bottle)
NDC 13107-082-01
traZODONE Hydrochloride Tablets, USP 300 mg Pharmacist: Please dispense with medication guide provided separately Rx only 100 Tablets AUROBINDO
- INGREDIENTS AND APPEARANCE
TRAZODONE HYDROCHLORIDE trazodone hydrochloride tablet Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:13107-079 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TRAZODONE HYDROCHLORIDE (UNII: 6E8ZO8LRNM) (TRAZODONE - UNII:YBK48BXK30) TRAZODONE HYDROCHLORIDE 50 mg Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) MAGNESIUM STEARATE (UNII: 70097M6I30) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) STARCH, CORN (UNII: O8232NY3SJ) SODIUM LAURYL SULFATE (UNII: 368GB5141J) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) Product Characteristics Color WHITE (white to off-white) Score 2 pieces Shape ROUND (Biconvex) Size 7mm Flavor Imprint Code J;43 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:13107-079-30 30 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 2 NDC:13107-079-01 100 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 3 NDC:13107-079-05 500 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 4 NDC:13107-079-99 1000 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204852 09/15/2015 TRAZODONE HYDROCHLORIDE trazodone hydrochloride tablet Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:13107-080 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TRAZODONE HYDROCHLORIDE (UNII: 6E8ZO8LRNM) (TRAZODONE - UNII:YBK48BXK30) TRAZODONE HYDROCHLORIDE 100 mg Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) MAGNESIUM STEARATE (UNII: 70097M6I30) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) STARCH, CORN (UNII: O8232NY3SJ) SODIUM LAURYL SULFATE (UNII: 368GB5141J) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) Product Characteristics Color WHITE (white to off-white) Score 2 pieces Shape ROUND (Biconvex) Size 10mm Flavor Imprint Code J;44 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:13107-080-30 30 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 2 NDC:13107-080-01 100 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 3 NDC:13107-080-05 500 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 4 NDC:13107-080-99 1000 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204852 09/15/2015 TRAZODONE HYDROCHLORIDE trazodone hydrochloride tablet Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:13107-081 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TRAZODONE HYDROCHLORIDE (UNII: 6E8ZO8LRNM) (TRAZODONE - UNII:YBK48BXK30) TRAZODONE HYDROCHLORIDE 150 mg Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) MAGNESIUM STEARATE (UNII: 70097M6I30) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) STARCH, CORN (UNII: O8232NY3SJ) SODIUM LAURYL SULFATE (UNII: 368GB5141J) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) Product Characteristics Color WHITE (white to off-white) Score 3 pieces Shape OVAL (Biconvex) Size 17mm Flavor Imprint Code J;45 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:13107-081-30 30 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 2 NDC:13107-081-01 100 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 3 NDC:13107-081-05 500 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 4 NDC:13107-081-99 1000 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204852 09/15/2015 TRAZODONE HYDROCHLORIDE trazodone hydrochloride tablet Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:13107-082 Route of Administration ORAL Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength TRAZODONE HYDROCHLORIDE (UNII: 6E8ZO8LRNM) (TRAZODONE - UNII:YBK48BXK30) TRAZODONE HYDROCHLORIDE 300 mg Inactive Ingredients Ingredient Name Strength SILICON DIOXIDE (UNII: ETJ7Z6XBU4) MAGNESIUM STEARATE (UNII: 70097M6I30) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) STARCH, CORN (UNII: O8232NY3SJ) SODIUM LAURYL SULFATE (UNII: 368GB5141J) SODIUM STARCH GLYCOLATE TYPE A POTATO (UNII: 5856J3G2A2) Product Characteristics Color WHITE (white to off-white) Score 3 pieces Shape OVAL (Biconvex) Size 21mm Flavor Imprint Code J;46 Contains Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:13107-082-30 30 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 2 NDC:13107-082-01 100 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 3 NDC:13107-082-05 500 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 4 NDC:13107-082-99 1000 in 1 BOTTLE; Type 0: Not a Combination Product 09/15/2015 Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA204852 09/15/2015 Labeler - Aurolife Pharma LLC (829084461) Establishment Name Address ID/FEI Business Operations Aurobindo Pharma Limited 918917642 ANALYSIS(13107-079, 13107-080, 13107-081, 13107-082) , MANUFACTURE(13107-079, 13107-080, 13107-081, 13107-082) Establishment Name Address ID/FEI Business Operations APL HEALTHCARE LIMITED 650918514 ANALYSIS(13107-079, 13107-080, 13107-081, 13107-082) , MANUFACTURE(13107-079, 13107-080, 13107-081, 13107-082)
Find additional resources
(also available in the left menu)Safety
Boxed Warnings, Report Adverse Events, FDA Safety Recalls, Presence in Breast Milk
Related Resources
Medline Plus, Clinical Trials, PubMed, Biochemical Data Summary
More Info on this Drug
View Labeling Archives, RxNorm, Get Label RSS Feed, View NDC Code(s)NEW!
TRAZODONE HYDROCHLORIDE tablet
Number of versions: 7
| Published Date (What is this?) | Version | Files |
|---|---|---|
| Jul 10, 2024 | 8 (current) | download |
| Nov 20, 2023 | 7 | download |
| May 30, 2023 | 6 | download |
| May 4, 2023 | 5 | download |
| Mar 30, 2023 | 4 | download |
| Jan 23, 2023 | 3 | download |
| Feb 12, 2020 | 2 | download |
TRAZODONE HYDROCHLORIDE tablet
| RxCUI | RxNorm NAME | RxTTY | |
|---|---|---|---|
| 1 | 856364 | traZODone HCl 150 MG Oral Tablet | PSN |
| 2 | 856364 | trazodone hydrochloride 150 MG Oral Tablet | SCD |
| 3 | 856369 | traZODone HCl 300 MG Oral Tablet | PSN |
| 4 | 856369 | trazodone hydrochloride 300 MG Oral Tablet | SCD |
| 5 | 856373 | traZODone HCl 100 MG Oral Tablet | PSN |
| 6 | 856373 | trazodone hydrochloride 100 MG Oral Tablet | SCD |
| 7 | 856377 | traZODone HCl 50 MG Oral Tablet | PSN |
| 8 | 856377 | trazodone hydrochloride 50 MG Oral Tablet | SCD |
TRAZODONE HYDROCHLORIDE tablet
To receive this label RSS feed
Copy the URL below and paste it into your RSS Reader application.
https://dailymed.nlm.nih.gov/dailymed/labelrss.cfm?setid=295e92a9-bcb0-4d53-ba62-e30020e9834b
To receive all DailyMed Updates for the last seven days
Copy the URL below and paste it into your RSS Reader application.
https://dailymed.nlm.nih.gov/dailymed/rss.cfm
What will I get with the DailyMed RSS feed?
DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.
DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. To view updated drug label links, paste the RSS feed address (URL) shown below into a RSS reader, or use a browser which supports RSS feeds, such as Safari for Mac OS X.
How to discontinue the RSS feed
If you no longer wish to have this DailyMed RSS service, simply delete the copied URL from your RSS Reader.
More about getting RSS News & Updates from DailyMedWhy is DailyMed no longer displaying pill images on the Search Results and Drug Info pages?
Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage, we no longer display the RxImage pill images associated with drug labels.
We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels.
TRAZODONE HYDROCHLORIDE tablet
If this SPL contains inactivated NDCs listed by the FDA initiated compliance action, they will be specified as such.
| NDC | |
|---|---|
| 1 | 13107-079-01 |
| 2 | 13107-079-05 |
| 3 | 13107-079-30 |
| 4 | 13107-079-99 |
| 5 | 13107-080-01 |
| 6 | 13107-080-05 |
| 7 | 13107-080-30 |
| 8 | 13107-080-99 |
| 9 | 13107-081-01 |
| 10 | 13107-081-05 |
| 11 | 13107-081-30 |
| 12 | 13107-081-99 |
| 13 | 13107-082-01 |
| 14 | 13107-082-05 |
| 15 | 13107-082-30 |
| 16 | 13107-082-99 |
- Home
- News
- DailyMed Announcements
- Get RSS News & Updates
- Search
- Advanced Search
- Browse Drug Classes
- Labels Archives
- FDA Resources
- NLM SPL Resources
- Download Data
- All Drug Labels
- All Index Files
- All Mapping Files
- SPL Image Guidelines
- Presentations & Articles
- Download Data
- Application Development Support
- Resources
- Web Services
- Mapping Files
- Resources
- Help
Từ khóa » C-079/99
-
C-079-99 Corte Constitucional De Colombia
-
C-079-99 | Procuraduría De La Administración
-
AMUNDI FUNDS EMERGING MARKETS GREEN BOND - I2 USD (C)
-
Dave's Drum Shop | Facebook
-
079-99: LEGISLATIVE HISTORY:
-
8 In Ratcheting Adjustable Wrench - 99-079 - Bostitch
-
[PDF] Relatoría Tribunal Superior De Tunja RELACIÓN LABORAL ...
-
NDC Code 65862-079-99 - Terbinafine Hydrochloride ...
-
AMUNDI INDEX GLOBAL AGG 500M - IG (C) | LU1437022277